CoChat

Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy

Open access
Borgegård, Tomas, Gustavsson, Susanne, Nilsson, Charlotte, Parpal, Santiago, Klintenberg, Rebecka, Berg, Anna-Lena, Rosqvist, Susanne, Serneels, Lutgarde, Svensson, Samuel, Olsson, Fredrik, Jin, Shaobo, Yan, Hongmei, Wanngren, Johanna, Jureus, Anders, Ridderstad-Wollberg, Anna, Wollberg, Patrik, Stockling, Kenneth, Karlström, Helena, Malmberg, Åsa, Lund, Johan, Arvidsson, Per I., De Strooper, Bart, Lendahl, Urban, Lundkvist, Johan · 2012 · The Journal of Neuroscience
Cited by 43

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

γ-Secretase inhibition represents a major therapeutic strategy for lowering amyloid β (Aβ) peptide production in Alzheimer's disease (AD). Progress toward clinical use of γ-secretase inhibitors has, however, been hampered due to mechanism-based adverse events, primarily related to impairment of Notch signaling. The γ-secretase inhibitor MRK-560 represents an exception as it is largely tolerable in vivo despite displaying only a small selectivity between Aβ production and Notch signaling in vitro. In exploring the molecular basis for the observed tolerability, we show that MRK-560 displays a strong preference for the presenilin 1 (PS1) over PS2 subclass of γ-secretases and is tolerable in wild-type mice but causes dose-dependent Notch-related side effect in PS2-deficient mice at drug exposure levels resulting in a substantial decrease in brain Aβ levels. This demonstrates that PS2 plays an important role in mediating essential Notch signaling in several peripheral organs during pharmacological inhibition of PS1 and provide preclinical in vivo proof of concept for PS2-sparing inhibition as a novel, tolerable and efficacious γ-secretase targeting strategy for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1451-12.2012

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 43

Metadata

Authors
Borgegård, T., Gustavsson, S., Nilsson, C., Parpal, S., Klintenberg, R., Berg, A.-L., Rosqvist, S., Serneels, L., Svensson, S., Olsson, F., Jin, S., Yan, H., Wanngren, J., Jureus, A., Ridderstad-Wollberg, A., Wollberg, P., Stockling, K., Karlström, H., Malmberg, Å., Lund, J., Arvidsson, P. I., De Strooper, B., Lendahl, U., & Lundkvist, J.
Venue
The Journal of Neuroscience
Published
2012-11-28
Volume
32
Issue
48
Pages
17297-17305
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2010724581
Cited by
43
References
5
FWCI
2.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy. https://app.cochat.ai/papers/10.1523/jneurosci.1451-12.2012
The paper
Borgegård, T., Gustavsson, S., Nilsson, C., Parpal, S., Klintenberg, R., Berg, A.-L., Rosqvist, S., Serneels, L., Svensson, S., Olsson, F., Jin, S., Yan, H., Wanngren, J., Jureus, A., Ridderstad-Wollberg, A., Wollberg, P., Stockling, K., Karlström, H., Malmberg, Å., . . . Lundkvist, J. (2012). Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1451-12.2012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.